Primary Objectives:~Describe differences in the PK profiles of terbutaline sulfate administered via the SQ route versus the IV route.~Estimate a target plasma concentration and IV dose which achieves maximum FEV1 improvement from baseline and FEV1 AUC.~Secondary Objective: Describe all adverse events (AEs) in participants receiving terbutaline sulfate.
The overall aim in Part 1 is to compare the pharmacokinetic (PK)/pharmacodynamics (PD) relationship in intravenous (IV) versus subcutaneous (SQ) terbutaline sulfate to identify the optimal IV dosing range for use in Part 2.~The overall aim in Part 2 is to evaluate the optimal IV dosing of terbutaline sulfate based on PD response and safety data.